U.S. Department of Health and Human Services
Drug Development
Reports
Displaying 11 - 20 of 27. 10 per page. Page 2.
Advanced SearchPrescription Drug Spending by Medicare Beneficiaries in Institutional and Residential Settings, 1998-2001
U.S. Department of Health and Human Services
Analysis of Supply, Distribution, Demand, and Access Issues Associated with Immune Globulin Intravenous (IGIV)
Contents IGIV Supply and Distribution - Key Findings IGIV Demand - Key Fundings IGIV Access Problems- Key Fundings Immune globulin intravenous (IGIV), also referred to as intravenous immune globulin (IVIG), is a valuable treatment for many seriously ill patients. Although the U.S.
Cost Effectiveness Considerations in the Approval and Adoption of New Health Technologies
Contents Background and Purpose Methodology Summary of Key Findings and Stakeholder Suggestions Conclusions and Policy Implications A.
Continuation of Drug Risk Adjustment
Prepared by: National Opinion Research Center (NORC) at the University of Chicago Prepared for:U.S. Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation
Compendium of Home Modification and Assistive Technology Policy and Practice Across States: Final Report
U.S. Department of Health and Human Services
Evaluation of New Measures of Assistive Technology and the Home Environment from the 2005 Pilot Study of Technology and Aging
U.S. Department of Health and Human Services
Development of an Assistive Technology and Environmental Assessment Instrument for National Surveys: Final Report
U.S. Department of Health and Human Services Development of an Assistive Technology and Environmental Assessment Instrument for National Surveys: Final Report Part I. Recommended Modules and Instrument Development Process
Impact of Policies to Limit Drug Plan's Financial Risk
This paper examines the combined effects of drug plan risk the first year of Medicare part D implementation of the combination of reinsurance, risk-adjustment and risk-corridors